What is the market capitalization of Immunovant, Inc.?

Immunovant, Inc. (IMVT) has a market capitalization of approximately 6,395,372,765 USD.

How many ETFs hold IMVT?

IMVT is held by 19 ETFs tracked on Investir en Bourse.

Where can I buy IMVT in Canada?

IMVT can be purchased through any Canadian online broker including Wealthsimple, Questrade, Qtrade, or RBC Direct Investing.

IMVT

Immunovant, Inc.

Immunovant, Inc. (IMVT) is an American company in the healthcare sector, listed on NASDAQ. Market capitalization of 6.4 billion USD (mid-cap).

Details

Price31.15 USD

Market cap6.4 G USD

Payout ratio0.00%

ROE-64.82%

Debt / Equity0.01%

SectorHealthcare

Websiteimmunovant.com

Updated 2h ago

Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.